ArticleJournal of neuro-oncology2026
A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases from differentiated thyroid carcinoma (DTC) are rare but associated with significantly worse prognosis compared to extracranial metastatic sites. Existing prognostic models for brain metastases are not tailored to DTC, limiting risk stratification and therapeutic guidance in this population.
methodsWe conducted a retrospective cohort study of 10,306 patients with DTC treated at a single tertiary cancer center from 2011 to 2025. Patients with radiologically or pathologically confirmed brain metastases were included. Multivariable Cox regression was used to identify independent prognostic factors for overall survival (OS), defined from the time of Brain metastases diagnosis. Based on these factors, we developed the Differentiated Thyroid Cancer Graded Prognostic Assessment (DTC-GPA) and evaluated its discriminatory performance using Harrell's C-index. External validation was performed using individual-level data from published case series identified via systematic review.
resultsOf 10,306 patients with DTC, 146 (1.4%) were found to have brain metastases. The median OS after Brain metastases diagnosis was 20.4 months. ECOG performance status ≥ 2 (HR, 2.67; 95% CI, 1.65-4.30; p < 0.001), presence of multiple brain metastases (HR, 2.30; 95% CI, 1.39-3.82; p = 0.002), and interval ≥ 3 years between primary DTC and Brain metastases diagnosis (HR, 1.84; 95% CI, 1.03-3.27; p = 0.03) were independently associated with worse OS. These three factors formed the DTC-GPA, assigning one point for each favorable variable (range: 0-3). Median OS by score group was 7.7 months (score 0), 22.9 months (score 1), and 61.3 months (score 2-3). The C-index was 0.70 in the derivation cohort and 0.68 in the external validation cohort of 83 patients.
conclusionsThe DTC-GPA is the first validated, disease-specific prognostic tool for patients with brain metastases from DTC. This simple, three-point score offers clinically meaningful risk stratification to guide treatment decisions and prognosis estimation in a rare and heterogeneous patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.